Program: Oral and Poster Abstracts
Session: 322. Disorders of Coagulation or Fibrinolysis: Poster II
Aim: To analyze rFVIIa safety and efficacy data in home treatment in clinical trials and registries.
Methods: A systematic review focusing on the efficacy and safety of rFVIIa for the management of congenital hemophilia A and B patients with inhibitors in the home setting was performed. Studies included in the review consisted of clinical trials (phase I-IV) and prospective and retrospective registries evaluating bleed management and prophylaxis.
Results: A detailed review identified 14 studies for treatment of bleeding (3 phase II, 2 phase III, 9 phase IV) in the home setting including studies reporting on standard doses (90 mcg/kg), high single doses (270 mcg/kg), and observational studies (dosing per physician direction). These studies captured 865 patients treated for 9,024 bleeding episodes (see Table 1), including 640 patients with 6,999 episodes in studies where efficacy was evaluable. Efficacy was consistently high across studies. The 10-year Japanese post-marketing study (F7HAEM-1947) required all adverse events to be reported irrespective of causality; one patient had visual field defect and suspected cerebral infarction, one central venous occlusion, and two others had events that are not clearly thrombotic (hemolytic uremic syndrome, acute renal failure). The only thromboembolic event (TE) reported in phase II-III studies was in 1 patient in the phase II adept™2 trial, which compared vatreptacog alpha with rFVIIa. Apart from the Japanese study, thrombotic rate was 1/7306 bleeds (0.014%).
Table 1. On demand treatment of bleeding with rFVIIa
Trial ID |
Phase |
Number of Patients |
Number of Bleeds |
Efficacy |
Safety |
F7HAEM-1510 |
II |
22 |
42 |
88% |
No TE |
F7HAEM-2068 |
II |
24 |
45 |
91-92% |
No TE |
NN7128-1907 (Pioneer 1) |
II |
23 |
359 |
84% |
No TE |
F7HT/USA/1/USA (US Home Trx ) |
III |
56 |
877 |
92% |
No TE |
NN1731-3562 (adept™2) |
III |
57 |
227 |
93% |
1 TE |
HRS/HTRS Registry (2000-2003) |
IV |
42 |
793 |
87% |
No TE |
HTRS Registry (2004-2008) |
IV |
129 |
2,041 |
89-93% |
No TE |
F7HAEM-1965 (DOSE) |
IV |
35 |
158 |
Not assessed |
No TE |
F7HAEM-3507 (ONE) |
IV |
102 |
496 |
85-96% |
No TE |
NN7025-3601 (SMART-7) |
IV |
51 |
511 |
Not reported (interim) |
No TE |
F7HAEM-3537 (UKHCDO Registry) |
IV |
139 |
1,356 |
Not reported |
No TE |
F7HAEM-1947 |
IV |
144* |
1,718* |
88% |
2TE† |
F7AHEM-1921 (WIRK Registry) |
IV |
14 |
269 |
90% |
No TE |
F7HAEM-3850 |
IV |
27 |
132 |
81%-92% |
No TE |
Total |
|
865 |
9,024 |
|
* Patients with evaluable efficacy.
† One visual field defect with suspected cerebral infarction, one central venous occlusion.
Two studies evaluated rFVIIa for secondary prophylaxis (1 phase II, 1 phase IV) (see Table 2). The phase II study captured 22 patients treated with 90 or 270 mcg/kg daily. The phase IV retrospective study captured 86 patients with varied rFVIIa doses that often changed over time. Effective reduction in bleeding was seen in both studies. Across 108 patients treated with prophylaxis at home over 42,861 days, there were no thrombotic events reported.
Table 2. Secondary Prophylaxis with rFVIIa
Trial ID |
Phase |
Number of Patients |
Number of Prophylaxis Days |
Efficacy |
Safety |
F7HAEM-1505 |
II |
22 |
1,885 |
45-59% reduction |
No TE |
F7HAEM-3695 (PRO-PACT) |
IV |
86 |
40,976 |
46-52% |
No TE |
Total |
|
108 |
42,861 |
|
Conclusions: Analysis of data from clinical studies of rFVIIa in home treatment of bleeding and secondary prophylaxis of bleeding demonstrates consistent efficacy for treatment and prevention of bleeding. Thrombotic events were uncommon across ~9,000 bleeding episodes and not reported in ~43,000 prophylaxis days. These data support the safety and efficacy of rFVIIa in the home treatment setting and sufficient evidence for payers to continue its approval in the home management of hemophilia patients.
Disclosures: Young: Kedrion: Consultancy ; Bayer: Consultancy ; Baxter: Consultancy ; Biogen Idec: Consultancy , Honoraria ; Novo Nordisk: Consultancy , Honoraria . Escobar: Novo Nordisk Inc.: Consultancy ; Baxter: Consultancy ; Bayer: Consultancy ; Pfizer: Consultancy ; Biogen: Consultancy ; CSL Behring: Consultancy . Pipe: Biogen Idec Inc: Consultancy ; CSL Behring: Consultancy ; Bayer: Consultancy ; American Thrombosis and Hemostasis Network: Other: Chair of the Board of Directors ; National Hemophilia Foundation: Other: member of the Medical and Scientific Advisory Committee ; Novo Nordisk: Consultancy ; Baxter: Consultancy . Cooper: Novo Nordisk Inc.: Employment .
See more of: Disorders of Coagulation or Fibrinolysis
See more of: Oral and Poster Abstracts
*signifies non-member of ASH